PMC:7507645 / 6343-8089
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7507645","sourcedb":"PMC","sourceid":"7507645","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7507645","text":"The following outcomes were assessed in patients with and without MO based on mean change from baseline (28-day pretreatment period) in the: monthly average number of headache days of at least moderate severity during the 12-week treatment period; monthly average number of migraine days during the 12-week treatment period; and monthly average number of days of any acute headache medication use. Also assessed was the proportion of patients with a ≥ 50% reduction from baseline (28-day pretreatment period) in the monthly average number of headache days of at least moderate severity during the 12-week treatment period; mean change from baseline (day 0) in scores on the six-item Headache Impact Test (HIT-6; scores range from 36 to 78, with higher scores indicating greater impact of headache on functional status and well-being) [18] at 4 weeks after the last dose of study drug; mean change from baseline (day 0) in domain scores on the Migraine-Specific Quality of Life (MSQoL) questionnaire (domains assessed: role function–restrictive [RFR; seven items on how migraines limit daily activities], role function–preventive [RFP; four items on how migraines prevent these activities], emotional function [EF; three items on the emotional effects of migraines]; scores range from 0 to 100, with higher scores indicating better health-related quality of life) [19] at 4 weeks after the last dose of study drug; and mean change from baseline (day 0) in scores on the nine-item Patient Health Questionnaire (PHQ-9; scores range from 0 to 27, with depression severity categorized as no or minimal [0 to 4], mild [5 to 9], moderate [10 to 14], moderately severe [15 to 19], and severe [20 to 27]) [20] at 4 weeks after the last dose of study drug.","tracks":[{"project":"TEST0","denotations":[{"id":"32958075-235-241-1506675","span":{"begin":1364,"end":1366},"obj":"[\"21929662\"]"},{"id":"32958075-235-241-1506676","span":{"begin":1697,"end":1699},"obj":"[\"11556941\"]"}],"attributes":[{"subj":"32958075-235-241-1506675","pred":"source","obj":"TEST0"},{"subj":"32958075-235-241-1506676","pred":"source","obj":"TEST0"}]},{"project":"2_test","denotations":[{"id":"32958075-21929662-60560882","span":{"begin":1364,"end":1366},"obj":"21929662"},{"id":"32958075-11556941-60560883","span":{"begin":1697,"end":1699},"obj":"11556941"}],"attributes":[{"subj":"32958075-21929662-60560882","pred":"source","obj":"2_test"},{"subj":"32958075-11556941-60560883","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"TEST0","color":"#93eccb","default":true},{"id":"2_test","color":"#ecb193"}]}]}}